Affordable Access

The standard Hancock porcine bioprosthesis: overall experience at the University of Padova.

Authors
  • Gallucci, V
  • Mazzucco, A
  • Bortolotti, U
  • Milano, A
  • Guerra, F
  • Thiene, G
Type
Published Article
Journal
Journal of cardiac surgery
Publication Date
Sep 01, 1988
Volume
3
Issue
3 Suppl
Pages
337–345
Identifiers
PMID: 2980035
Source
Medline
License
Unknown

Abstract

All patients undergoing aortic (AVR, n = 196), mitral (MVR, n = 502), and mitral-aortic (MAVR, n = 71) valve replacement with a standard Hancock porcine bioprosthesis (HPB) from 1970 to 1983 were reviewed. A total of 665 patients discharged were followed for 5,099 patient-years with an actuarial survival at 15 years of 52% +/- 4.5%, for MVR, 37% +/- 14% for AVR, and at 12 years of 52 +/- 7.4% for MAVR. Embolic episodes occurred in 9 patients after AVR (0.7% +/- 0.2% pt-yr), in 61 after MVR (1.7% +/- 0.2% pt-yr), and in 6 after MAVR (1.7% +/- 0.7% pt-yr); actuarial freedom from emboli at 15 years is 91% +/- 3.5% after AVR, 79% +/- 14% after MVR, and at 12 years is 87% +/- 5% after MAVR. Reoperation because of primary tissue failure (PTF) was performed in 47 patients with AVR (3.9% +/- 0.5% pt-yr), 91 with MVR (2.6% +/- 0.3% pt-yr), and in 13 with MAVR (4.1% +/- 1.1% pt-yr); actuarial freedom from PTF at 15 years is 41% +/- 5.5% after MVR, 37% +/- 10% after AVR, and at 12 years is 49% +/- 13% after MAVR. After AVR and MVR, freedom from PTF is significantly better for patients over 50 years of age.(ABSTRACT TRUNCATED AT 250 WORDS)

Report this publication

Statistics

Seen <100 times